Bioartificial organ grafts: a view at the beginning of the third millennium.
An immunoisolated collection of cells, which communicate and exchange essential factors, co-stimulatory hormones, as well as providing immunoprotection and immunomodulation, can be prepared, given existing scientific and medical know-how, within two decades. These "Bioartificial Organ Grafts" have advantages relative to isolated cell therapies, including beta-cell encapsulation for diabetes treatment, and xenotransplantation, which has a de facto moratorium. This paper documents that the majority of the research for the bioartificial organ grafts has been concluded, with the remaining hurdles minimum in comparison. The use of co-encapsulation and the induction of local immune-privilege will provide a more sensitive humoral hormonal response and graft survival, without systemic immunosuppression. A call for the staged implementation of bioartificial organ grafts, based on the best available medical practice, materials, tissue and technology available, is advocated. The implementation of bioartificial organ grafts can begin within the next two years, based on allografts succeeded by genetically modified human tissue, without the need to pass through a xenograft stage.
Hunkeler
D
D
AQUA + TECH Specialties SA, Geneva, Switzerland. david.hunkeler@aquaplustech.ch
Rajotte
R
R
Grey
D
D
Morel
Ph
P
Skjak-Break
G
G
Korbutt
G
G
Gill
R
R
Oberholzer
J
J
D021522:Bioartificial Organs / Q000639:trends*; D017690:Cell Transplantation; D003920:Diabetes Mellitus / Q000628:therapy; D015316:Genetic Therapy; D006801:Humans; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous